Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) EV-to-Revenue

: 277.96 (As of Today)

View and export this data going back to 2000. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lexicon Pharmaceuticals's enterprise value is $334.94 Mil. Lexicon Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.21 Mil. Therefore, Lexicon Pharmaceuticals's EV-to-Revenue for today is 277.96.

The historical rank and industry rank for Lexicon Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

LXRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.57 Med: 24.19 Max: 1685.69
Current: 277.96

During the past 13 years, the highest EV-to-Revenue of Lexicon Pharmaceuticals was 1685.69. The lowest was 0.57. And the median was 24.19.

LXRX's EV-to-Revenue is ranked worse than
89.63% of 1032 companies
in the Biotechnology industry
Industry Median: 7.615 vs LXRX: 277.96

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-18), Lexicon Pharmaceuticals's stock price is $1.63. Lexicon Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Lexicon Pharmaceuticals's PS Ratio for today is 271.67.

Lexicon Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Lexicon Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

1.29

14.36

1,685.47

1,995.71

258.12

Lexicon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																1,995.71	3,256.26	1,004.13	291.04	258.12

Competitive Comparison

For the Biotechnology subindustry, Lexicon Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexicon Pharmaceuticals EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's EV-to-Revenue falls into.

Lexicon Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lexicon Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	334.942	/	1.205
	=	277.96

Lexicon Pharmaceuticals's current Enterprise Value is $334.94 Mil.
Lexicon Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.21 Mil.

Lexicon Pharmaceuticals (NAS:LXRX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lexicon Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.63	/	0.006
	=	271.67

Lexicon Pharmaceuticals's share price for today is $1.63.
Lexicon Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

Lexicon Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381

Website

https://www.lexpharma.com

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Executives

Philippe Amouyal	director	C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats	director, officer: President and CEO	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner	officer: SVP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade	officer: EVP, Gen. Counsel	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott	officer: VP, Human Resources	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a.	director, 10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc	director, 10 percent owner	750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth	officer: VP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub	officer: SVP, Regulatory & QA	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander	officer: VP, Finance and Accounting	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz	officer: SVP, Chief Medical Officer	58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer	officer: VP, Finance & Acctg	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381